Advances in Minimal Residual Disease Testing in Myeloma Meeting

MRD Banner

On July 10 in NYC, the MMRF helped host the “Advances in Minimal Residual Disease Testing in Multiple Myeloma” meeting at Memorial Sloan Kettering Cancer Center. This meeting brought together representatives from the US Food and Drug Administration (FDA), National Cancer Institute (NCI), and the biotechnology/pharmaceutical industry, as well as key opinion leaders to discuss the latest developments around minimal residual disease (MRD) in multiple myeloma. The meeting was organized by Dr. Ola Landgren, MD, PhD, Chief Myeloma Service, Memorial Sloan Kettering Cancer Center, Professor of Medicine at the Weill Cornell Medical College, and Peter Brodhead, Chief, CME Office, Office of Physician-in Chief, Memorial Sloan Kettering Cancer Center.

During the first portion of this meeting, participants reviewed the advances and new data from ongoing trials that have emerged in the last 12 months since the last meeting in the field of MRD testing for myeloma patients.

Next, a debate session tackled the following questions:

  • Should MRD be an endpoint for all clinical trials for myeloma?
  • Is MRD ready for prime time in standard clinical care?
  • Is MRD ready as a regulatory endpoint in myeloma?

During the last portion of the meeting, participants worked on formulating a consensus around uniform MRD testing criteria and laying a path for the use of MRD in clinical trials as well as in routine care. The day closed with a live webcast that recapped the deliberations and recommendations from the assembled participants. The goal of this meeting was to produce recommendations and an action plan on how to move forward with MRD testing in multiple myeloma, now.

From left to right, Dr. Gary Kelloff, NCI; Dr. Ola Landgren, Memorial Sloan Kettering Cancer Center; Dr. Nicole Gormley, FDA

Dr. Gary Kelloff, NCI and Walter Capone, CEO MMRF

Dr. Gareth Morgan, UAMS, Dr. Guenther Koehne and Dr. Ola Landgren, Memorial Sloan Kettering Cancer Center

The audience looks on as Dr. Tahamtan Ahmadi from Janssen Pharmaceuticals describes his “dream” MRD clinical study.


Click Here to download the program book.

Click Here to watch the live stream from the meeting.

The MMRF gratefully acknowledges our corporate sponsors:

MMRF Sponsor Logos

Leave a Reply

Your email address will not be published. Required fields are marked *